Nitric oxide synthase inhibitor improves de novo and long-term l-DOPA-induced dyskinesia in hemiparkinsonian rats

Frontiers in Systems Neuroscience

Volumn , Issue JUNE 2011, 2011, Pages

  Padovan Neto, Fernando Eduardo ^a   Echeverry, Marcela Bermúdez ^a,b   Chiavegatto, Silvana ^a   Del Bel, Elaine ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDAD DE SANTANDER   (Colombia)

Author keywords

Abnormal involuntary movements; FosB FosB; L DOPA induced dyskinesia; Nitric oxide; Nitric oxide synthase; Nitric oxide synthase inhibitors; Parkinson's disease; Striatum

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LEVODOPA; MESSENGER RNA; N(G) NITROARGININE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; OXIDOPAMINE; TRANSCRIPTION FACTOR FOSB; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG INDUCED DISEASE; DYSKINESIA; ENZYME INHIBITION; EXPERIMENTAL TEST; FRONTAL CORTEX; GENE EXPRESSION; GENE OVEREXPRESSION; GROOMING; HIPPOCAMPUS; MALE; NONHUMAN; OPEN FIELD TEST; PARKINSONISM; PREFRONTAL CORTEX; PROTEIN EXPRESSION; RAT; REARING; STEPPING TEST;

EID: 82655177921     PISSN: 16625137     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnsys.2011.00040     Document Type: Article

References (74)

1. Abreu-González, P., González-Hernández, T., Afonso-Oramas, D., Cruz-Muros, I., Barroso-Chinea, P., González, M., and C. (2006). Tetrahydrobiopterin stimulates l-DOPA release from striatal tissue. Eur. J. Pharmacol. 541, 33-37.
2. Andersson, M., Hilbertson, A., and Cenci, M. A. (1999). Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6, 461-474.
3. Aquilano, K., Baldelli S., Rotilio G, and Ciriolo MR. (2008). Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem. Res. 33, 2416-2426.
4. Barone, P. (2010). Neurotransmission in Parkinson's disease: beyond dopamine. Eur. J. Neurol. 17, 364-376.
5. Barthwal, M. K., Srivastava, N., and Dikshit, M. (2001). Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat. Redox Rep. 6, 297-302.
6. Bibancos, T., Jardim, D. L., Aneas, I., and Chiavegatto, S. (2007). Social isolation and expression of serotonergic neuro-transmission-related genes in several brain areas of male mice. Genes Brain Behav. 6, 529-539.
7. Böckelmann, R., Wolf, G., Ransmayr, G., and Riederer, P. (1994). NADPH- diaphorase/nitric oxide synthase containing neurons in normal and Parkinson's disease putamen. J. Neural Transm. Park. Dis. Dement. Sect. 7, 115-121.
8. Calabrese, V., Bates, T. E., and Stella, A. M. (2000). NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/anti-oxidant balance. Neurochem. Res. 25, 1315-1341.
9. Calabresi, P., Centonze, D., Gubellini, P., Marfia, G. A., Pisani, A., Sancesario, G., and Bernardi, G. (2000). Synaptic transmission in the striatum: from plasticity to neurodegeneration. Prog. Neurobiol. 61, 231-265.
10. Cenci, M. A., and Konradi, C. (2010). Maladaptive striatal plasticity in l-DOPA-induced dyskinesia. Prog. Brain Res. 183, 209-233.
11. Cenci, M. A., Lee, C. S., and Bjorklund, A. (1998). L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10, 2694-2706.
12. Cenci, M. A., Whishaw, I. Q., and Schallert, T. (2002). Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neurosci. 3, 574-579.
13. Centonze, D., Picconi, B., Gubellini, P., Bernardi, G., and Calabresi, P. (2001). Dopaminergic control of synaptic plasticity in the dorsal striatum. Eur. J. Neurosci. 13, 1071-1077.
14. Chalimoniuk, M., and Langfort, J. (2007). The effect of subchronic, intermittent l-DOPA treatment on neuronal nitric oxide synthase and soluble guanylyl-cyclase expression and activity in the striatum and midbrain of normal and MPTP-treated mice. Neurochem. Int. 50, 821-833.
15. Chalimoniuk, M., Stepie, A., and Strosznajder, J. B. (2004). Pergolidemesylate, a dopaminergic receptor agonist, applied with l-DOPA enhances serum antioxidant enzyme activity in Parkinson disease. Clin. Neuropharmacol. 27, 223-229.
16. Chang, J. W., Wachtel, S. R., Young, D., and Kang, U. J. (1999). Biochemical and anatomical characterization of fore-paw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88, 617-628.
17. Cools, A. R. (1980). Role of the neostriatal dopaminergic activity in sequencing and selecting behavioural strategies: facilitation of processes involved in selecting the best strategy in a stressful situation. Behav. Brain Res. 1, 361-378.
18. Darmopil, S., Martín, A. B., De Diego, I. R., Ares, S., and Moratalla, R. (2009). Genetic inactivation of dopamine D1 but not D2 receptors inhibits LDOPA- induced dyskinesia and histone activation. Biol. Psychiatry 66, 603-613.
19. Dehmer, T., Lindenau, J., Haid, S., Dichgans, J., and Schulz, J. B. (2000). Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 74, 2213-2216.
20. Del-Bel, E., Padovan-Neto, F. E., Raisman- Vozari, R., and Lazzarini, M. (2011). Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment. Curr. Pharm. Des. 17, 471-488.
21. Del-Bel, E. A., Guimarães, F. S., Bermudez- Echeverry, M., Gomes, M. Z., Schiaveto-De-Souza, A., Padovan- Neto, F., Tumas, V., Barion-Cavalcanti, A. P., Lazzarini, M., Nucci-Da-Silva, L. P., and de Paula-Souza, D. (2005). Role of nitric oxide on motor behavior. Cell. Mol. Neurobiol. 25, 371-392.
22. De-Vente, J., Van Ittersum, M., van Abeelen, J., Emson, P. C., Axer, H., and Steinbusch, H. W. M. (2000). NO-mediated cGMP synthesis in cho-linergic neurons in the rat forebrain: effects of lesioning dopaminergic or serotonergic pathways on nNOS and cGMP synthesis. Eur. J. Neurosci. 12, 507-519.
23. Di Giovanni, G., Ferraro, G., Sardo, P., Galati, S., Esposito, E., and La Grutta, V. (2003). Nitric oxide modulates striatal neuronal activity via soluble guanylylcyclase: an in vivo microion-tophoretic study in rats. Synapse 48, 100-107.
24. Duncan, A. J., and Heales, S. J. (2005). Nitric oxide and neurological disorders. Mol. Aspects Med. 26, 67-96.
25. Dunnett, S. B., and Robbins, T. W. (1992). The functional role of mesotelence-phalic dopamine systems. Biol. Rev. Camb. Philos. Soc. 67, 491-518.
26. Ebadi, M., and Sharma, S. K. (2003). Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antioxid. Redox Signal. 5, 319-335.
27. Eve, D., Nisbet, A., Kingsbury, A., Hewson, E., Daniel, S., Lees, A., Marsden, C., and Foster, O. (1998). Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Brain Res. Mol. Brain Res. 63, 62-71.
28. Galati, S., D'Angelo, V., Scarnati, E., Stanzione, P., Martorana, A., Procopio, T., Sancesario, G., and Stefani, A. (2008). In vivo electrophysiology of dopamine-denervated striatum: focus on the nitric oxide/cGMP signaling pathway. Synapse 62, 409-420.
29. Garthwaite, J. (2008). Concepts of neural nitric oxide-mediated transmission. Eur. J. Neurosci. 27, 2783-2802.
30. Gomes, M. Z., and del Bel, E. A. (2003). Effects of electrolytic and 6-hydroxy-dopamine lesions of rat nigrostriatal pathway on nitric oxide synthase and nicotinamide adenine dinucleotide phosphate diaphorase. Brain Res. Bull. 62, 107-115.
31. Gomes, M. Z., Raisman-Vozari, R., and del Bel, E. A. (2008). A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway. Brain Res. 1203, 160-169.
32. Guix, F. X., Uribesalgo, I., Coma, M., and Munoz, F. J. (2005). The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol. 76, 126-152.
33. Henry, B., Crossman, A. R., and Brotchie, J. M. (1998). Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-OHDA-lesioned rat model of Parkinson's disease. Exp. Neurol. 151, 334-342.
34. Hunot, S., Boissière, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y., and Hirsch, E. (1996). Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72, 355-363.
35. Iancu, R., Mohapel, P., Brundin, P., and Paul, G. (2005). Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav. Brain Res. 162, 1-10.
36. Itokawa, K., Ohkuma, A., Araki, N., Tamura, N., and Shimazu, K. (2006). Effect of l-DOPA on nitric oxide production in striatum of freely mobile mice. Neurosci. Lett. 402, 142-144.
37. Jenner, P. (2008). Molecular mechanisms of l-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 9, 665-677.
38. Kavya, R., Saluja, R., Singh, S., and Dikshit, M. (2008). Nitric oxide synthase regulation and diversity: implications in Parkinson's disease. Nitric Oxide 15,280-294.
39. Kawaguchi, Y. (1997). Neostriatal cell subtypes and their functional roles. Neurosci. Res. 27, 1-8.
40. Konitsiotis, S., and Tsironis, C. (2006). Levodopa-induced dyskinesia and rotational behavior in hemiparkin-sonian rats: independent features or components of the same phenomenon? Behav. Brain Res. 170, 337-341.
41. Kubota, Y., Mikawa, S., and Kawaguchi, Y. (1993). Neostriatal GAB Aergicinterneurones contain NOS, calretinin or parvalbumin. Neuroreport 5, 205-208.
42. Lane, E. L., Cheetham, S. C., and Jenner, P. (2006). Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complica-tions as well as therapeutic effects in Parkinson's disease? Exp. Neurol. 197, 284-290.
43. Lane, E. L., Soulet, D., Vercammen, L., Cenci, M. A., and Brundin, P. (2008). Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease. Neurobiol. Dis. 32, 220-228.
44. Lundblad, M., Andersson, M., Winkler, C., Kirik, D., Wierup, N., and Cenci, M. (2002). Pharmacological valida-tion of behavioural measures of aki-nesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci.15, 120-132.
45. Marsden, C. D., and Parkes, J. D. (1977). Success and problems of long-term levodopa therapy in Parkinson's dis-ease. Lancet 1, 345-349.
46. Miller, R., and Beninger, R. J. (1991). On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animals with unilateral depletion of striatal dopamine. Prog. Neurobiol. 36, 229-256.
47. Monville, C., Torres, E. M., and Dunnett, S. B. (2006). Comparison of incre-mental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model. J. Neurosci. Methods 158, 219-223.
48. Morello, M., Reiner, A., Sancesario, G., Karle, E. J., and Bernardi, G. (1997). Ultrastructural study of nitric oxide synthase-containing striatal neurons and their relationship with parvalbu-min-containing neurons in rats. Brain Res. 776, 30-39.
49. Mura, A., Mintz, M., and Feldon, J. (2002). Behavioral and anatomical effects of long-term l-dihydroxyphenylalanine (l-DOPA) administration in rats with unilateral lesions of the nigrostriatal system. Exp. Neurol. 177, 252-264.
50. Novaretti, N., Padovan-Neto, F. E., Tumas, V., Da-Silva, C. A., and del Bel, E. A. (2010). Lack of tolerance for the anti- dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibi-tor, in rats. Braz. J. Med. Biol. Res. 43, 1047-1053.
51. Olsson, M., Nikkhah, G., Bentlage, C., and Björklund, A. (1995). Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new step-ping test. J. Neurosci. 15, 3863-3875.
52. Padovan-Neto, F. E., Echeverry, M. B., Tumas, V., and Del-Bel, E. A. (2009). Nitric oxide synthase inhibition attenuates l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neuroscience 159, 927-935.
53. Papa, S. M., Engber, T. M., Kask, A. M., and Chase, T. N. (1994). Motor fluctuations in levodopa treated Parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 662, 69-74.
54. Pavón, N., Martín, A., Mendialdua, A., and Moratalla, R. (2006). ERK phos-phorylation and FosB expression are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol. Psychiatry 59, 64-74.
55. Paxinos, G., and Watson, C. (1998). The Rat Brain in Stereotaxic Coordinates. New York: Academic Press.
56. Ponzoni, S., Guimarães, F. S., Del Bel, E. A., and Garcia-Cairasco, N. (2000). Behavioral effects of intra-nigral microinjections of manganese chlo-ride: interaction with nitric oxide. Prog. Neuropsychopharmacol. Biol. Psychiatry 24, 307-325.
57. Przedborski, S., Jackson-Lewis, V., Yokoyama, R., Shibata, T., Dawson, V. L., and Dawson, T. M. (1996). Role of neuronal nitric oxide in 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neu-rotoxicity. Proc. Natl. Acad. Sci. U.S.A. 93, 4565-4571.
58. Qureshi, G. A., Baig, S., Bednar, I., Sodersten, P., Forsberg, G., and Siden, A. (1995). Increased cerebro-spinal fluid concentration of nitrite in Parkinson's disease. Neuroreport 6, 1642-1644.
59. Sancesario, G., Giorgi, M., D'angelo, V., Modica, A., Martorana, A., Morello, M., Bengtson, C. P., and Bernardi, G. (2004). Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriataldeafferentation. Eur. J. Neurosci. 20, 989-1000.
60. Sanchez, J. J., Abreu, P., and Gonzalez, M. C. (2002). Sodium nitroprus-side stimulates l-DOPA release from striatal tissue through nitric oxide and cGMP. Eur. J. Pharmacol. 438, 79-83.
61. Santini, E., Alcacer, C., Cacciatore, S., Heiman, M., Hervé, D., Greengard, P., Girault, J. A., Valjent, E., and Fisone, G. (2009). l-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemipa-rkinsonian mice. J. Neurochem. 108, 621-633.
62. Schwarting, R. K., Bonatz, A. E., Carey, R. J., and Huston, J. P. (1991). Relationships between indices of behavioral asymmetries and neurochemical changes following mesencephalic 6-hydroxy-dopamine injections. Brain Res. 554, 46-55.
63. Schwarting, R. K., and Huston, J. P. (1996). Unilateral 6-OHDA lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog. Neurobiol. 49, 215-266.
64. Sullivan, R. M., Fraser, A., and Szechtman, H. (1994). Asymmetrical orientation to edges of an open field: modulation by striatal dopamine and relationship to motor asymmetries in the rat. Brain Res. 637, 114-118.
65. Tepper, J. M., and Bolam, J. P. (2004). Functional diversity and specificity of neostriatal interneurons. Curr. Opin. Neurobiol. 14, 685-692.
66. Trabace, L., Cassano, T., Tucci, P., Steardo, L., Kendrick, K. M., and Cuomo, V. (2004). The effects of nitric oxide on striatal serotoninergic transmission involve multiple targets: an in vivo microdialysis study in the awake rat. Brain Res. 2008, 293-298.
67. Tuite, P., and Riss, J. (2003). Recent developments in the pharmacological treatment of Parkinson's disease. Expert. Opin. Investig. Drugs 12, 1335-1352.
68. Ungerstedt, U., and Arbuthnott, G. W. (1970). Quantitative recording of rota-tional behavior in rats after 6-hydroxy- dopamine lesions of thenigrostriatal dopamine system. Brain Res. 24, 485-493.
69. Vandesompele, J., de Preter, K., Pattyn, F., Poppe, B., van Roy, N., de Paepe, A., and Speleman, F. (2002). Accurate normalization of real-time quantitative RT-PCR data by geo-metric averaging of multiple internal control genes. Genome Biol. 3, research0034.1-research0034.11.
70. West, A. R., and Grace, A. A. (2002). Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J. Neurosci. 22, 294-304.
71. West, A. R., and Grace, A. A. (2004). The nitric oxide-guanylylcyclase signaling pathway modulates membrane activity states and electrophysiological properties of striatal medium spiny neurons recorded in vivo. J. Neurosci. 24, 1924-1935.
72. Winkler, C., Kirik, D., Björklund, A., and Cenci, M. A. (2002). l-DOPA-induced dyskinesia in the intrastriatal 6-OHDA model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10, 165-186.
73. Zetterström, T., Herrera-Marschitz, M., and Ungerstedt, U. (1986). Simultaneous measurement of dopa-mine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Res. 376, 1-7.
74. Zhang, J., Graham, D. G., Montine, T. J., and Ho, Y. S. (2000). Enhanced N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dis-mutase or glutathione peroxidase. J. Neuropathol. Exp. Neurol. 59, 53-61.